ArQule, Inc. to Report Third Quarter 2009 Financial Results on Thursday, November 5, 2009

ArQule, Inc. (NASDAQ: ARQL) today announced that it will report its financial results for the third quarter of 2009 in a press release to be issued on Thursday, November 5, 2009 at 7:00 a.m. eastern time. The Company will host a conference call and web cast to discuss these results at 9:00 a.m. eastern time on that day.

Conference call details

A replay of the conference call will be available beginning at 12:00 p.m. on November 5, 2009 for seven days and can be accessed by dialing toll-free 888-286-8010 and outside the U.S. 1-617-801-6888. The access code is 86035092.

About ArQule

ArQule is a biotechnology company engaged in the research and development of next-generation, small-molecule cancer therapeutics. The Company’s targeted, broad-spectrum products and research programs are focused on key biological processes that are central to cancer. ArQule’s lead product, in Phase 2 clinical development, is ARQ 197, an inhibitor of the c-MET receptor tyrosine kinase. The Company has also initiated Phase 1 clinical testing with ARQ 621, designed to inhibit the Eg5 kinesin motor protein. An additional clinical-stage program includes compounds that activate the cell’s DNA damage response mechanism mediated by the E2F-1 transcription factor. The Company’s pre-clinical pipeline includes a compound designed to inhibit the BRAF kinase. ArQule’s current discovery efforts, which are based on the ArQule Kinase Inhibitor Platform (AKIP™) are focused on the identification of novel kinase inhibitors that are potent, selective and do not compete with ATP (adenosine triphosphate) for binding to the kinase.